2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Biological activity
Description
CAS NO.：60-89-9 Product Name：10H-Phenothiazine,10-[(1-methyl-3-piperidinyl)methyl]- Synonyms：10H-Phenothiazine,10-[(1-methyl-3-piperidinyl)methyl]-;10-[(1-methylpiperidin-3-yl)methyl]phenothiazine;Pecazine;Pecazine-d3;10-(1-methyl-[3]piperidylmethyl)-phenothiazine;10-(1-methyl-piperidin-3-ylmethyl)-10H-phenothiazine;10-[(1-methyl-3-piperidinyl)methyl]-10H-phenothiazine;Lacumin;mepasin;Mepazin;MEPAZINE;Meprazine;Nothiazine;Pacatal;Pakatal;Pecatal EINEC: Molecular Formula：C19H22N2S Molecular Weight：310.45638
Target:
In Vivo
Mepazine (16 mg/kg; intraperitoneal administration) interferes with growth and induces apoptosis of ABC-DLBCL cell line OCI-Ly10 in NOD/scid IL-2Rgnull (NSG) mice with a murine DLBCL xenogeneic tumor model. Daily administration of Mepazine strongly impairs the expansion of the ABC-DLBCL cell line OCI-Ly10[1]. Animal Model: 6- to 8-week-old female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice with a murine DLBCL xenogeneic tumor model[1] Dosage: 400 μg per animal (25 g), corresponding to approximately 16 mg/kg. Administration: Intraperitoneal administration; started 1 or 12 days after transplantation and given continuously every 24 hr; daily application Result: Daily administration strongly impaired the expansion of the ABC-DLBCL cell line OCI-Ly10.
In Vitro
Mepazine (5-20 μM; 4 days) causes a decrease of cell viability in the activated B cell subtype of diffuse large B cell lymphoma (ABCDLBCL) cells, without significantly affecting GCB-DLBCL cells[1]. Cell Viability Assay[1] Cell Line: ABC-DLBCL cell lines (HBL1, OCI-Ly3, U2932, TMD8, OCI-Ly10) and GCB-DLBCL cell lines (BJAB, Su-DHL-6, Su-DHL-4) Concentration: 5, 10, and 20 μM Incubation Time: 4 days Result: Caused a decrease of cell viability in the ABC-DLBCL cells HBL1, OCI-Ly3, U2932, and TMD8, without significantly affecting GCB-DLBCL cells.
Kinase Assay
Cell Assay
Animal Administration
References
[1]. Nagel D, et al. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. Cancer Cell. 2012 Dec 11;22(6):825-37.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
